Berry Consultants Releases FACTS 7 Clinical Trial Simulator

Author of the article: Published Apr 12, 2023  •  3 minute read FACTS 7 includes new module for Platform Trial designs AUSTIN, Texas — Berry Consultants, LLC announced today that FACTS 7 was released to existing users and is now available to all new clients. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most…
Berry Consultants Releases FACTS 7 Clinical Trial Simulator

Author of the article:

Published Apr 12, 2023  •  3 minute read

FACTS 7 includes new module for Platform Trial designs

AUSTIN, Texas — Berry Consultants, LLC announced today that FACTS 7 was released to existing users and is now available to all new clients. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, flexible, and fastest simulation tool on the market for advanced clinical trial design. FACTS covers the whole spectrum of trial designs, from early development phase I trials, to innovative phase II trials, and efficient phase III designs. With the release of FACTS 7 and the new platform trial module, FACTS becomes the first commercially available and validated software for the design and simulation of adaptive platform trials.

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

  • Unlimited online access to articles from across Canada with one account
  • Get exclusive access to the National Post ePaper, an electronic replica of the print edition that you can share, download and comment on
  • Enjoy insights and behind-the-scenes analysis from our award-winning journalists
  • Support local journalists and the next generation of journalists
  • Daily puzzles including the New York Times Crossword

Subscribe now to read the latest news in your city and across Canada.

  • Unlimited online access to articles from across Canada with one account
  • Get exclusive access to the National Post ePaper, an electronic replica of the print edition that you can share, download and comment on
  • Enjoy insights and behind-the-scenes analysis from our award-winning journalists
  • Support local journalists and the next generation of journalists
  • Daily puzzles including the New York Times Crossword

Create an account or sign in to continue with your reading experience.

  • Access articles from across Canada with one account
  • Share your thoughts and join the conversation in the comments
  • Enjoy additional articles per month
  • Get email updates from your favourite authors

Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails or any newsletter. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

The Berry Consultants team is the internationally renowned leader in the creation, design, and implementation of platform trials in many disease areas such as ALS, Breast Cancer, Alzheimer’s, Pancreatic Cancer, Glioblastoma Multiforme, Influenza, Pneumonia, and COVID-19, and is currently expanding platform trials into many more disease areas for sponsors. These platform trials are built with a master protocol to allow multiple therapies to be investigated in a single trial, being added continuously, all with shared infrastructure. In addition, a platform trial allows multiple arms to share a common control, share the common infrastructure of the trial, and it allows the better treatment of patients in the trial. The platform trial concept is a win-win for all stakeholders – smaller sample size, reduced patients on placebo, reduced costs, reduced timelines, and better inferences for regulators. Now with FACTS 7, this innovative approach of platform trials can be shared to commercial clients through licensing the FACTS software package.

Scott Berry, PhD, President and Senior Statistical Scientist at Berry Consultants, said, “This is an exciting day for our FACTS software and all of its users. This new design module and software release transforms FACTS to allow users to design an efficient adaptive platform trial. There are so many advantages of platform trials and now FACTS allows for thorough and efficient simulation for optimizing these trials.”

This initial platform trial module of FACTS 7 allows users to simulate trials where many treatments are tested, with treatments entering and leaving the trial over time. Its current simulation capabilities are for continuous and dichotomous endpoints with various trial level participant and arm constraints. In particular, users can specify a maximum enrollment time, number of participants, definition of successful treatments, participants per arm and concurrent treatments. In addition, it has the capability to simulate treatments arriving at different times during the trial and provide allocation options that include fixed proportion to control, allocation ratios dependent on the number of treatments and response adaptive randomization.

Tom Parke, Director of Software Solutions of Berry Consultants, added, “We are thrilled to be able to take some of the concepts and approaches of platform trials from the Berry Consultants scientific team and be able to apply that to our FACTS software. This new module brings some initial capabilities and features to our FACTS users as a first step, and we will be continuing to develop this platform trial software in future releases. We will continue to develop FACTS and provide to our users the latest and most innovative features in clinical trial design.”

With this release, FACTS continues to share a common structure, platform and philosophy: that simulation of clinical trials should be easy to set up, flexible, fast to run, and clear in their outcomes. FACTS allows users to specify trials across the whole spectrum from the simplest and widely used to the most innovative.

About Berry Consultants

Berry Consultants is a statistical consulting company specializing in innovative clinical trial design, analysis, execution, and software solutions for the pharmaceutical and medical device industry. We employ world-renowned experts in Bayesian statistics and strive to set the standard for adaptive clinical trial design and analysis across all medical disciplines. www.berryconsultants.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005122/en/

Contacts

Berry Consultants

(512) 213-6428

[email protected]

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
Strategic Investor Crescat Capital LLC to Acquire Up to 19.9% Ownership in Goliath Resources
Read More

Strategic Investor Crescat Capital LLC to Acquire Up to 19.9% Ownership in Goliath Resources

Author of the article: TORONTO, Feb. 15, 2022 (GLOBE NEWSWIRE) — Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (Frankfurt: B4IF) (the “Company” or “Goliath”) is pleased to announce that Crescat Capital LLC (“Crescat”) a strategic investor has agreed to acquire up to 19.9% post funding of the $11,000,000 non-brokered private placement announced by Goliath earlier…
Gold as Inflationary Hedge Makes Turkey World’s Biggest Buyer
Read More

Gold as Inflationary Hedge Makes Turkey World’s Biggest Buyer

Turkey was the biggest buyer of gold among central banks last year, with households also rushing to buy the commodity to shield from geopolitical uncertainty and rampant inflation. Author of the article: Bloomberg News Kerim Karakaya and Beril Akman Published Jan 31, 2023  •  2 minute read Join the conversation 2zhupr8vk5{sj{i07ls33{]1_media_dl_1.png Bloomberg RSS (Bloomberg) —…